世界主要国における卵巣癌（Ovarian Cancer）治療市場（～2020）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 9
2.1 Disease Pathophysiology 9
2.1.1 Ovarian Cancer – A Group of Distinct Diseases 9
2.1.2 Ovarian Cancer is Highly Heterogenic, with Multiple Mutations and Affected Signaling Pathways 10
2.2 Symptoms and Diagnosis 12
2.3 Risk Factors 13
2.3.1 Age 13
2.3.2 Inherited Genetic Mutations 13
2.3.3 Greater Number of Lifetime Ovulations 14
2.3.4 Weight 14
2.3.5 Previous Medical Conditions 14
2.4 Treatment Algorithm 14
2.4.1 Surgery 14
2.4.2 First-Line Chemotherapy 14
2.4.3 Maintenance Therapy 18
2.5 Recurrent Disease 20
3 Marketed Products 36
3.1 Carboplatin 36
3.2 Paclitaxel 37
3.3 Gemcitabine 38
3.4 Topotecan 40
3.5 Pegylated Liposomal Doxorubicin 41
3.6 Yondelis 42
3.7 Avastin 43
4 Product Pipeline 45
4.1 Overview of Pipeline by Phase and Route of Administration 45
4.2 Overview of Pipeline by Molecule Type, Mechanism of Action and Molecular Target 47
4.2.1 Molecular Targets in the Developmental Pipeline 48
4.3 Clinical Trials 53
4.3.1 Clinical Trial Duration 53
4.3.2 Clinical Trial Size 54
4.3.3 Failure Rate 57
4.3.4 Discussion 59
5 Late-Stage Drugs in Developmental Pipeline 61
5.1 Profiles 61
5.1.1 Niraparib 61
5.1.2 Olaparib 62
5.1.3 Abagovomab 64
5.1.4 Vargatef 65
5.1.5 Trebananib 66
5.1.6 Farletuzumab 70
5.1.7 Vynfinit 71
5.1.8 Telcyta 73
5.1.9 Karenitecin 75
5.2 Discussion 83
6 Market Forecast 84
6.1 Global Market 84
6.1.1 Overview 84
6.1.2 Treatment Patterns and Revenues in Top Eight Markets 85
6.2 North America 88
6.2.1 Treatment Usage Patterns 88
6.2.2 Annual Cost of Therapy 90
6.2.3 Market Revenues 92
6.3 Top Five European Markets 94
6.3.1 Treatment Usage Patterns 94
6.3.2 Annual Cost of Therapy 96
6.3.3 Market Forecasts 97
6.4 Japan 100
6.4.1 Treatment Usage Patterns 100
6.4.2 Annual Cost of Therapy 101
6.4.3 Market Forecast 102
7 Drivers and Barriers 104
7.1 Drivers 104
7.1.1 High Number of Candidates in Drug Development 104
7.1.2 High Unmet Clinical Need 104
7.1.3 Incentives for Orphan Drug Development 104
7.1.4 Potential Changes to Clinical Trial Design 105
7.2 Barriers 105
7.2.1 Decreasing Incidence Rates 105
7.2.2 Lack of Cell Lines 105
7.2.3 High Heterogeneity of the Disease 105
7.2.4 High Cost of Novel Drugs 105
8 Deals 106
8.1 Licensing Deals 106
8.1.1 Clovis Oncology Enters into Licensing Agreement with Pfizer for PF-01367338 108
8.1.2 PharmaMar Enters into Licensing Agreement with Janssen for Yondelis 108
8.1.3 Hana Enters into Licensing Agreement with Tekmira 109
8.1.4 AstraZeneca Enters into Licensing Agreement with Merck for MK-1775 109
8.1.5 Tesaro Enters into Licensing Agreement with Merck Sharp & Dohme for Cancer Drug 109
8.1.6 Oasmia Enters into Licensing Agreement with Medison for Paclical 110
8.1.7 Orion Enters into Agreement with Oasmia 110
8.1.8 Ohio University Enters into Licensing Agreement with Phosplatin 110
8.1.9 Genta Enters into Licensing Agreement with Daiichi Sankyo 110
8.1.10 Celldex Enters into Licensing Agreement with the Ludwig Institute for Cancer Research 110
8.1.11 NanoCarrier Enters into Licensing Agreement with Kowa for NC-6300 111
8.2 Co-Development Deals 111
8.2.1 Merck Enters into Co-Development Agreement with Endocyte for Cancer Drug 112
8.2.2 Pfizer Enters into Research Agreement with BC Cancer Agency and Vancouver Prostate Centre 113
8.2.3 Almac Discovery Enters into an Agreement with Queen’s University Belfast for Drug Discovery 113
9 Appendix 114
9.1 All Pipeline Drugs by Phase 114
9.1.1 Discovery 114
9.1.2 Preclinical 116
9.1.3 IND/CTA-Filed 122
9.1.4 Phase I 123
9.1.5 Phase II 128
9.1.6 Phase III 133
9.1.7 Pre-Registration 134
9.2 Market Forecasts to 2020 134
9.2.1 Global 134
9.2.2 The US 134
9.2.3 Canada 135
9.2.4 UK 135
9.2.5 France 136
9.2.6 Germany 136
9.2.7 Italy 137
9.2.8 Spain 137
9.2.9 Japan 138
9.3 Abbreviations 139
9.4 Bibliography 141
9.5 Methodology 147
9.6 Secondary Research 147
9.7 Contact Us 148
9.8 Disclaimer 148